EGFR exon 19 insertions: A new family of sensitizing EGFR mutations in lung adenocarcinoma

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1790-1797

  He, Mai ^a   Capelletti, Marzia ^c   Nafa, Khedoudja ^a   Yun, Cai Hong ^c   Arcila, Maria E ^a   Miller, Vincent A ^a   Ginsberg, Michelle S ^a   Zhao, Binsheng ^a   Kris, Mark G ^a,b   Eck, Michael J ^c   Jänne, Pasi A ^c   Ladanyi, Marc ^a   Oxnard, Geoffrey R ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; XL 647;

ADJUVANT THERAPY; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SIZE; CARCINOGENICITY; CELL PROLIFERATION; CELL TRANSFORMATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; EXON; FEMALE; GENE INSERTION; GENE MUTATION; GENE STRUCTURE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 84858201603     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2361     Document Type: Article

References (42)

1. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
2. Douillard J-Y, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2009;28:744-52.
3. Janne PA, Wang XF, Socinski MA, Crawford J, Capelletti M, Edelman MJ, et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 28:15s, 2010 (suppl; abstr 7503).
4. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-7.
5. Riely GJ, Chaft JE, Ladanyi M, Kris MG. Incorporation of Crizotinib into the NCCN Guidelines. J Natl Compr Canc Netw 2011;9: 1328-30.
6. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46. (Pubitemid 40425952)
7. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
8. Wu JY, Wu SG, Yang CH,Gow CH, Chang YL, Yu CJ, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008;14: 4877-82.
9. Wu J-Y, Yu C-J, Chang Y-C, Yang JC-H, Shih J-Y, Yang P-C. Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-21.
10. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-8. (Pubitemid 44299146)
11. Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski M, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M Mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169-80.
12. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26.
13. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23. (Pubitemid 39665498)
14. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23: 2513-20. (Pubitemid 47050841)
15. Yoshida Y, Shibata T, Kokubu A, Tsuta K, Matsuno Y, Kanai Y, et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005;50:1-8. (Pubitemid 41297463)
16. Okami J, Taniguchi K, Higashiyama M, Maeda J, Oda K, Orita N, et al. Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. Oncology 2007;72:234-42. (Pubitemid 351161616)
17. Ilie MI, Hofman V, Bonnetaud C, Havet K, Lespinet-Fabre V, Coelle C, et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010;457:483-95.
18. Job B, Bernheim A, Beau-Faller M, Camilleri-Broet S, Girard P, Hofman P, et al. Genomic aberrations in lung adenocarcinoma in never smokers. PLoS One 2010;5:e15145.
19. Uruga H, Kishi K, Fujii T, Beika Y,Enomoto T, Takaya H, et al. Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med 2010;49:103-7.
20. De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, et al. Activity of Epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011;6: 1895-901.
21. Dogan S, Ang DC, Brzostowski E, Johnson ML, D'Angelo SP, Paik PK, et al. EGFR and KRAS mutations in 3026 consecutive lung adenocarcinomas: associations with age, sex, and smoking history. J Mol Diagn 2010;12:908.
22. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403. (Pubitemid 41149655)
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
24. Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 2010;16: 4647-53.
25. Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor response-initial results. Radiology 2006;241:892-8. (Pubitemid 46190557)
26. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-4.
27. Engelman JA, Zejnullahu K, Gale C-M, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-32.
28. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-27. (Pubitemid 46349842)
29. Warmuth M, Kim S, Gu XJ, Xia G, Adrian F. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 2007;19:55-60. (Pubitemid 44885601)
30. Pietanza MC, Lynch TJ, Lara PN, Cho J, Yanagihara RH, Vrindavanam N, et al. XL647, a multi-targeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol 2012;7:219-26.
31. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17:5530-7.
32. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011;6:1379-91.
33. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 2008;3:832-9.
34. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66: 8163-71. (Pubitemid 44299184)
35. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105: 2070-5. (Pubitemid 351439466)
36. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007;58:324-8. (Pubitemid 350051507)
37. Janne P, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, et al. Phase I dose-escalation study of the pan-HER Inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17:1131-9.
38. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009;4:e7887.
39. Kris MG, Lau CY, Ang D, Brzostowski E, Riely GJ, Rusch VW, et al. Initial results of LC-MAP: an institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma. J Clin Oncol 28:15s, 2010 (suppl; abstr 7009).
40. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22: 2616-24.
41. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44. (Pubitemid 43259866)
42. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-9. (Pubitemid 39297926)